|
1
|
Demetri GD, von Mehren M, Blanke CD, van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dematteo RP, Ballman KV, Antonescu CR,
Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von
Mehren M, Brennan MF, et al; American College of Surgeons Oncology
Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant
imatinib mesylate after resection of localised, primary
gastrointestinal stromal tumour: a randomised, double-blind,
placebo-controlled trial. Lancet. 373:1097–1104. 2009. View Article : Google Scholar
|
|
3
|
Joensuu H, Eriksson M, Hatrmann J, Sundby
Hall K, Schutte J, Reichardt M, Schlemmer M, Wardelmann E, Ramadori
G, Al-Batran S, et al: Twelve versus 36 months of adjuvant imatinib
(IM) as treatment of operable GIST with a high risk of recur-
rence: final results of a randomized trial (SSGXVIII/AIO). J Clin
Oncol. 29(Suppl): LBA12011.
|
|
4
|
Le Cesne A, Ray-Coquard I, Bui BN, Adenis
A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A,
et al; French Sarcoma Group. Discontinuation of imatinib in
patients with advanced gastrointestinal stromal tumours after 3
years of treatment: an open-label multicentre randomised phase 3
trial. Lancet Oncol. 11:942–949. 2010.PubMed/NCBI
|
|
5
|
Blay JY, Le Cesne A, Ray-Coquard I, Bui B,
Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, et al:
Prospective multicentric randomized phase III study of imatinib in
patients with advanced gastrointestinal stromal tumors comparing
interruption versus continuation of treatment beyond 1 year: the
French Sarcoma Group. J Clin Oncol. 25:1107–1113. 2007.
|
|
6
|
Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ,
Sohn HJ, Lee JS and Kang YK: Clinical outcome in gastrointestinal
stromal tumor patients who interrupted imatinib after achieving
stable disease or better response. Jpn J Clin Oncol. 36:704–711.
2006. View Article : Google Scholar
|
|
7
|
Casali PG and Blay JY;
ESMO/CONTICANET/EUROBONET Consensus Panel of Experts.
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5):
v98–v102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti
H, Rubin BP, Shmookler B, Sobin LH and Weiss SW: Diagnosis of
gastrointestinal stromal tumors: a consensus approach. Hum Pathol.
33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antonescu CR, Besmer P, Guo T, Arkun K,
Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer
S, et al: Acquired resistance to imatinib in gastrointestinal
stromal tumor occurs through secondary gene mutation. Clin Cancer
Res. 11:4182–4190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahon FX, Réa D, Guilhot J, Guilhot F,
Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B,
et al; Intergroupe Français des Leucémies Myéloïdes Chroniques.
Discontinuation of imatinib in patients with chronic myeloid
leukaemia who have maintained complete molecular remission for at
least 2 years: the prospective, multicentre Stop Imatinib (STIM)
trial. Lancet Oncol. 11:1029–1035. 2010.PubMed/NCBI
|
|
12
|
von Mehren M, Heinrich M, Joensuu H,
Blanke CD, Wehrle E and Demetri GD: Follow-up results after 9 years
(yrs) of the ongoing, phase II B2222 trial of imatinib mesylate
(IM) in patients (pts) with metastatic or unresectable KIT+
gastrointestinal stromal tumors (GIST). J Clin Oncol. 29(Suppl):
100162011.
|
|
13
|
Mussi C, Ronellenfitsch U, Jakob J,
Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and
Gronchi A: Post-imatinib surgery in advanced/metastatic GIST: is it
worthwhile in all patients? Ann Oncol. 21:403–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gronchi A, Fiore M, Miselli F, Lagonigro
MS, Coco P, Messina A, Pilotti S and Casali PG: Surgery of residual
disease following molecular-targeted therapy with imatinib mesylate
in advanced/metastatic GIST. Ann Surg. 245:341–346. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hohenberger P, Schneider U, Pink D,
Emmerich K, Kettelhack C, Roetschke O and Reichardt P: Resection of
progressive or residual tumor after treatment with imatinib for
advanced GI stromal tumors. Ann Surg Oncol. 11(Suppl): 532004.
View Article : Google Scholar
|
|
16
|
DeMatteo RP, Maki RG, Singer S, Gonen M,
Brennan MF and Antonescu CR: Results of tyrosine kinase inhibitor
therapy followed by surgical resection of metastatic
gastrointestinal stromal tumor. Ann Surg. 245:347–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bonvalot S, Eldweny H, Péchoux CL, Vanel
D, Terrier P, Cavalcanti A, Robert C, Lassau N and Cesne AL: Impact
of surgery on advanced gastrointestinal stromal tumors (GIST) in
the imatinib era. Ann Surg Oncol. 13:1596–1603. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rutkowski P, Nowecki Z, Nyckowski P,
Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M
and Ruka W: Surgical treatment of patients with initially
inoperable and/or metastatic gastrointestinal stromal tumors (GIST)
during therapy with imatinib mesylate. J Surg Oncol. 93:304–311.
2006. View Article : Google Scholar
|
|
19
|
Raut CP, Posner M, Desai J, Morgan JA,
George S, Zahrieh D, Fletcher CD, Demetri GD and Bertagnolli MM:
Surgical management of advanced gastrointestinal stromal tumors
after treatment with targeted systemic therapy using kinase
inhibitors. J Clin Oncol. 24:2325–2331. 2006. View Article : Google Scholar
|
|
20
|
Mitry E, Fields AL, Bleiberg H, Labianca
R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, et
al: Adjuvant chemotherapy after potentially curative resection of
metastases from colorectal cancer: a pooled analysis of two
randomized trials. J Clin Oncol. 26:4906–4911. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al; EORTC Gastro-Intestinal Tract Cancer
Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen
und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie
(ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG);
Fédération Francophone de Cancérologie Digestive (FFCD).
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery
alone for resectable liver metastases from colorectal cancer (EORTC
Intergroup trial 40983): a randomised controlled trial. Lancet.
371:1007–1016. 2008. View Article : Google Scholar
|
|
22
|
Gold JS, Gönen M, Gutiérrez A, Broto JM,
García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF,
Antonescu CR, Donohue JH and DeMatteo RP: Development and
validation of a prognostic nomogram for recurrence-free survival
after complete surgical resection of localised primary
gastrointestinal stromal tumour: a retrospective analysis. Lancet
Oncol. 10:1045–1052. 2009. View Article : Google Scholar
|
